BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 23, 2006
View Archived Issues
Shell Firm Acquiring Protalix, Phase III Gaucher's Therapy
Public shell company Orthodontix Inc. is gaining a Phase III-ready drug for Gaucher's disease along with a plant-cell bioreactor for making proteins in its merger with Israeli firm Protalix Ltd. (BioWorld Today)
Read More
Belgian Firm Peakadilly Gets €14.5M In Series A
No Abstract
Read More
Anthracycline Prodrug Added To Innovive's Cancer Pipeline
Read More
Thiakis Series A Brings In £10M For Obesity Program
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More
Other News To Note
Read More